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Multi-parametric magnetic resonance imaging is an emerging imaging modality for diagno-
sis, staging, characterization, and treatment planning of prostate cancer. In this report, we
reviewed the literature for studies assessing the accuracy of multi-parametric magnetic res-
onance imaging in detecting clinically significant prostate cancer, and we critically examined
the future role of this imaging tool in various clinical diagnostic settings.There is accumulat-
ing evidence suggesting a high accuracy of multi-parametric magnetic resonance imaging in
ruling out clinically significant disease. Although definition for clinically significant disease
widely varies, the negative predictive value is very high at up to 98%. Multi-parametric
magnetic resonance imaging should, thus, be further evaluated for application in different
clinical scenarios in which it is desirable to reduce the proportion of unnecessary prostate
biopsies and to limit the detection of indolent disease, such as opportunistic screening,
persistent prostate cancer suspicion in men with previous negative prostate biopsies, and
eligibility for active surveillance. Continued improvement in standardization of technical
parameters, functional sequences, and image reporting systems is a pre-requisite for a
rapid and successful dissemination of this imaging modality.
Keywords: prostate neoplasms, magnetic resonance imaging, prostate biopsy, screening, active surveillance,
radical prostatectomy
BACKGROUND
In one large randomized trial, prostate-cancer (PCa) screening has
resulted in a reduction in risk of metastatic disease and cancer-
specific mortality (1). However, a major concern of screening is
overdiagnosis of cases that would not have caused clinical con-
sequences if left untreated (2). Overdiagnosis, in turn, leads to
overtreatment, with the potential for unnecessary side effects
related to curative treatments. Strategies to reduce overdiagno-
sis are mandatory, as are strategies to differentiate indolent from
aggressive tumors. Novel biomarkers, such as serum/urine markers
(e.g., PSA isoform-based “Prostate Health Index” and PCA3) and
advanced imaging techniques (e.g., functional magnetic resonance
imaging [MRI]) hold promise for their potential to improve accu-
racy in detecting clinically significant PCa. However, none of them
is ready to be integrated into clinical practice because large-scale
validation is lacking.
Owing to its high soft tissue contrast and high resolution,
MRI provides a better visualization of the prostate and its lesions
compared to transrectal ultrasound (TRUS) and other imaging
modalities (3). Over the past years, its use has shifted from stag-
ing purpose to that of detection of PCa thanks to refinement in
image acquisition protocols and introduction of functional tech-
niques. The availability of higher field strength magnets (3 T),
increased number of phased array receiver coils, and improved
pulse-sequence techniques has resulted in a greater signal-to-
noise ratio and, thus, increased spatial resolution (4). Moreover,
the increasing utilization of so-called “multi-parametric MRI”
(MP-MRI), deriving from the combination of conventional mor-
phological T2-weighted sequences with at least two of the newest
functional techniques, i.e., diffusion-weighted imaging (DWI),
dynamic contrast-enhanced (DCE) imaging, and magnetic reso-
nance spectroscopic imaging (MRSI), has further improved the
capability to locate and characterize prostate lesions (4). DWI
quantifies the microscopic mobility of water molecules in the
extracellular extravascular space, providing information on cell
density. PCa exhibits a reduced diffusion of water compared
to normal prostate tissue due to hypercellularity with a relative
decrease in water content and to disruption of interstitial spaces
through which water normally diffuses. DCE imaging uses a bolus
of intravenous gadolinium contrast, followed by a series of rapid
sequential scans at short time intervals, to generate maps of tis-
sue perfusion. High-grade tumors typically show an early and
intense contrast enhancement followed by a rapid washout. MRSI
allows for the assessment of cell metabolism by displaying the rel-
ative concentrations of citrate, choline, creatine, and polyamines.
Intracellular levels of choline and creatine increase, while those
of citrate decrease in malignant lesions, and are associated with
tumor volume and grade (4).
Due to these peculiarities, MP-MRI has been studied in various
clinical settings:
• Opportunistic screening.
• Selecting men for repeat prostate biopsy.
• Informing/guiding prostate biopsy.
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FIGURE 1 | Multi-parametric magnetic resonance imaging in a
65-year-old man referred for early detection of prostate cancer with an
elevated serum PSA level (7 ng/ml) and a normal digital rectal
examination. Magnetic resonance imaging consisted of conventional
T2-weighted, diffusion-weighted, and dynamic contrast-enhanced
sequences performed on a 3T unit without endorectal coil. (A) An ovoidal
hyperintense lesion (arrow) was observed on axial diffusion-weighted
imaging at b-value 1000 s/mm2 in left apical peripheral zone. (B) The lesion
(arrow) corresponded to hypointense lesion on apparent diffusion
coefficient map. (C) The lesion (arrow) also corresponded to axial
T2-weighted image with low signal intensity, and to (D) focal enhanced
lesion on axial dynamic contrast-enhanced imaging with a type 3
enhancement curve (washout) (E). The final Prostate Imaging Reporting
and Data System score for this lesion was four. The presence of a clinically
significant cancer was confirmed with a targeted biopsy, showing an 8-mm
Gleason score 4+3 adenocarcinoma.
• Selecting men for active surveillance.
• Monitoring tumour progression during active surveillance.
• Clinical staging.
• Treatment selection.
• Surgical planning (e.g., nerve-sparing radical prostatectomy).
• Focal therapy planning.
• Radiation therapy planning.
In two recent review articles, the use of MP-MRI-derived tar-
gets to guide biopsy has been shown to significantly improve PCa
detection over systematic TRUS-guided prostate biopsy (PB), with
sensitivity rates up to 80% for cancers located in the peripheral
zone (5, 6). In fact, accurate lesion localization with MP-MRI
enables a targeted biopsy, which overcomes the limitations inher-
ent to the conventional systematic TRUS-guided PB, such as
sampling error and undersampling of poorly accessible prostate
regions (e.g., anterior gland). This high diagnostic performance is
particularly evident in the setting of repeat PB after previous neg-
ative systematic TRUS-guided PB, where cancer is detected in up
to 63% of patients using MRI-guidance, with up to 87% of these
cancers qualifying as clinically significant (6). In addition, accu-
mulating data suggest that the newest functional sequences, par-
ticularly DWI where a quantitative image analysis is possible, have
the ability to differentiate between low- and intermediate-/high-
grade tumors, at least for those cancers located in the peripheral
zone (7, 8).
In an attempt to standardize the reporting of MP-MRI, in 2012
an expert panel of the European Society of Urogenital Radiology
(ESUR) introduced the Prostate Imaging Reporting and Data Sys-
tem (PI-RADS) as part of the MRI guidelines for prostate imaging
(9). According to this semi-objective scoring system, each suspi-
cious prostate lesion is assigned a point between one and five for
each sequence performed as part of MP-MRI, with one being most
likely clinically non-significant and five being most likely clini-
cally significant disease. Figure 1 shows an example of clinically
significant disease.
Based on all these premises, MP-MRI is a strong candidate tool
for the detection of aggressive PCa, with the potential to reduce
the number of unnecessary biopsies and the rate of overdetection
and overtreatment.
Thus, the aim of this report is to review the literature for studies
assessing the accuracy of MP-MRI in detecting clinically signifi-
cant PCa, and to critically examine the future role of this imaging
tool in various clinical diagnostic settings.
MULTI-PARAMETRIC MRI AND CLINICALLY SIGNIFICANT
PROSTATE-CANCER: LITERATURE EVIDENCE
Although there is agreement that detection of “clinically signifi-
cant disease” should be the primary aim of any diagnostic tool for
PCa, no consensus on its definition has been reached (10). From
a methodological standpoint, this is a major obstacle to assess this
outcome measure in a proper and systematic manner.
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Several studies are available that have been designed to address
the question as to whether MP-MRI is able to in detecting “clin-
ically significant disease.” In this non-systematic mini-review, we
present only those series reporting full data on diagnostic accu-
racy (11–16). Details of the six included studies are reported in
Table 1. Of them, four were prospective and two retrospective
cohort studies. Included were patients undergoing both initial and
repeat PB with varying PSA ranges. Only in one study (12), there
was also a minority of men already diagnosed with low-risk PCa.
Histology at PB was the reference standard in all studies. Different
modalities for PB were used, ranging from transperineal template
mapping to TRUS-guided sampling using cognitive or visual reg-
istration of the MRI target or registration software fusing MRI
images with real-time TRUS. In addition, MP-MRI protocols and
image acquisitions were not uniform, as well as statistical methods
of analysis. Finally, four studies (11, 12, 14, 15) originated from
the same researchers’ group, introducing a possible publication
bias.
Due to all these reasons, the performance of MP-MRI in detect-
ing “clinically significant disease” varied considerably across the
studies. Accuracy, positive predictive value and negative predictive
value ranged from 23 to 80%, 6 to 82%, and 47 to 100%, respec-
tively (Table 1). It is notable, however, that the negative predictive
value, albeit decreasing with higher thresholds for the definition of
“clinically significant disease,” remained relatively high, implying
that MP-MRI is a reliable tool to rule out potentially aggressive
tumors.
CURRENT CHALLENGES OF MULTI-PARAMETRIC MRI IN
DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER
The ESUR PI-RADS is based on opinion of experts, is currently
undergoing changes and refinements and still awaits a formal val-
idation (17). Such validation study should include a design where
MP-MRI is performed prior to PB, several readers blinded to
clinical data and with different experience in prostate MP-MRI
evaluate independently the images, MRI-targeted PB is compared
to systematic TRUS-guided PB, and the reference standard is final
pathology of radical prostatectomy specimens with and without
preoperatively known PCa so as to reduce the bias in which readers
are aware that the study population comprises only patients with
proven PCa. To the best of our knowledge, only a single diagnostic
study on MRI used final pathology of prostates with and without
cancer as the reference standard, having enrolled patients eventu-
ally treated with RP or radical cystectomy (18). This study, how-
ever, was not powered to address the issue of false positives with
only 18 patients with no PCa. Moreover, only DW sequences were
used. Thus, a refinement of the existing semi-objective scoring
systems with focus on clinically significant disease is warranted.
Moreover, the accuracy of image reporting is strongly depen-
dent on reader expertise. Taken the results of two recent studies
in aggregate (19, 20), subjective scoring (so-called Likert scales)
by experienced readers results in more accurate characterization
of the likelihood of malignancy of prostate lesions seen at MP-
MRI than do the semi-objective scores, such as the PI-RADS
and morphology-location-signal intensity scale. It is reasonable to
think that this is also the case for the characterization of clinically
significant disease.
In order to disseminate in the clinical practice, MP-MRI
should be standardized not only with regard to image reporting
systems, but also with regard to technical equipment, exami-
nation protocols, and image acquisition, processing and post-
processing. Moreover, future studies should always assess inter-
observer variability among expert and junior readers, and learn-
ing curve for both MP-MRI readers and operators performing
MRI-informed PB (if different from readers). Communication
between low-volume centers and high-volume centers should be
promoted with training programs and tele-courses. Clinically sig-
nificant disease should be the primary outcome measure in such
studies.
Furthermore, histology parameters available at MRI-targeted
biopsy may not necessarily have the same value of those available
at systematic TRUS-guided PB. With the former, there is typically
an upgrade in Gleason score and a higher percentage of cancer
per core compared to the latter. Therefore, a new definition of
“clinically significant disease” will be required. Validation of these
“new” risk parameters is mandatory to determine the true value of
pre-biopsy MRI.
In addition, whether MRI-targeted biopsies should be always
complemented by systematic TRUS-guided PB during first and
repeat PB setting remains unknown. When transperineal satura-
tion biopsy is set as the reference standard, approximately 10%
of men with “negative” MP-MRI performed by experienced high-
volume radiologists still harbor intermediate-risk disease (21). It
is plausible that with increasing precision in MRI-targeted biopsy
technology, systematic biopsies will lose their value.
Finally, costs related to this sophisticated imaging technology
are still an issue for many radiological centers worldwide. A formal
cost-effectiveness analysis is eagerly awaited.
THE FUTURE DIAGNOSTIC ROLE OF MULTI-PARAMETRIC MRI
Based on the relatively high negative predictive value for “clini-
cally significant disease,” it might not be impossible for MP-MRI
to become a first-line screening tool. This would entail a major
paradigm shift in PCa. By optimizing diagnosis, and subsequently
preventing overtreatment of clinically insignificant disease, MP-
MRI-informed PB may provide a method for streamlining the
diagnostic pathway in PCa. A recent prospective trial in PB-
naïve men has provided promising results with this regard (22).
Compared to systematic TRUS-guided PB, a diagnostic pathway
including MP-MRI and selective MP-MRI-guided biopsy of equiv-
ocal or suspicious lesions reduced the need for biopsy by 51%,
decreased the diagnosis of low-risk PCa by 89.4%, and increased
the detection of intermediate/high-risk PCa by 17.7%.
With increasing adoption of scanners with higher strength
fields (i.e.,3 T) ensuring a better image quality without an endorec-
tal coil, patient acceptance is expected to increase. On the other
hand, it remains to be proven whether DCE-MRI has an addi-
tional diagnostic value compared to DW-MRI with conventional
T2-weighted MRI, particularly for the detection of significant dis-
ease (23). Furthermore, the use of MRSI is decreasing because
it requires an endorectal coil even using high strength fields,
complex software, a longer training to achieve proficient image
interpretation and a long reading time. If DW-MRI alone com-
bined with conventional T2-weighted MRI would prove to be
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Table 1 | Main characteristics of the selected studies evaluating multi-parametric magnetic resonance imaging in detecting clinically significant prostate cancer and reporting full data on
diagnostic accuracy.
First author
[reference]
N Study
design
Prostate biopsy
status
Reference standard Level of analysis
for MP-MRI
performance
Overall
cancer
detection
rate (%)
Definition of clinically
significant cancer
Diagnostic performance of MP-MRI for
clinically significant cancer
Acc (%) Sen (%) Spe (%) PPV (%) NPV (%)
Rouse (11) 114 P Biopsy-naïve Systematic+ targeted
(cognitive) US-guided
transrectal biopsy
Whole prostate 60 GS≥7 and maximum
CCL≥3 mm
GS≥7 and maximum
CCL≥5 mm
64 91.5 44.8 53.8 88.2
61.4 92.9 43.1 48.8 91.2
Arumainayagam
(12)a
64 R Biopsy-
naïve+previous
negative
biopsy+previous
positive biopsy
TPMB Whole
prostate/prostate
halvesc
84 UCL2 criteria 72/74/72 88/90/95 44/48/30 74/75/71 67/73/78
UCL1 criteria 64/65/61 88/88/94 37/38/23 61/62/58 73/73/78
Goto’s criteria 73/79/80 83/87/94 44/56/38 82/85/82 47/60/67
Epstein’s criteria 73/79/77 85/89/94 44/56/33 80/83/78 53/67/67
GS≥7 75/73/66 100/97/100 48/47/29 67/66/60 100/93/100
Rais-Bahrami
(13)b
583 P Biopsy-naïve Systematic+ targeted
(MRI/US
fusion-guided)
transrectal biopsy
Whole prostate 54 GS≥7 NA 94/33 28/92 38/67 91/75
GS≥8 NA 98/45 24/89 18/41 91/91
Abd-Alazeez
(14)b
129 R Biopsy naïve TPMB Prostate halves 55 UCL2 criteria 44/68 94/68 23/69 34/48 89/83
UCL1 criteria 42/67 98/81 22/66 21/34 98/94
GS≥4+3 23/62 100/92 19/61 6/11 100/99
GS≥3+4 36/66 93/70 21/65 24/35 92/89
maximum CCL≥6 mm 33/67 98/80 21/65 19/30 98/95
maximum CCL≥4 mm 40/68 94/81 22/67 28/42 91/88
Abd-Alazeez
(15)b
54 P Previous negative
biopsy
TPMB Prostate halves 63 UCL2 criteria 53/80 76/67 42/85 38/67 79/85
UCL1 criteria 51/70 90/80 42/80 26/47 95/94
GS≥4+3 41/71 100/79 38/71 7/12 100/99
GS≥3+4 52/79 87/74 42/80 29/50 92/92
maximum CCL≥6 mm 49/78 89/77 41/78 23/41 95/94
maximum CCL≥4 mm 48/75 74/62 39/79 29/49 82/86
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Table 1 | Continued
First author
[reference]
N Study
design
Prostate biopsy
status
Reference standard Level of analysis
for MP-MRI
performance
Overall
cancer
detection
rate (%)
Definition of clinically
significant cancer
Diagnostic performance of MP-MRI for
clinically significant cancer
Acc (%) Sen (%) Spe (%) PPV (%) NPV (%)
Thompson (16) 150 P Biopsy-naïve TPMB+ targeted
(cognitive) US-guided
transperineal biopsy
Whole prostate 61 GS≥7 NA 94 50 52 94
GS≥7 with>5%
Gleason grade 4
96 47 43 96
GS≥6 with≥20%
positive cores or
maximum CCL≥5 mm
93 53 58 92
GS≥6 with>5%
Gleason grade 4,≥30%
positive cores or
maximum CCL≥8 mm
96 50 50 96
Acc, accuracy; CCL, cancer core length; Epstein’s criteria, Gleason score≥7 or PSA density≥0.1 ng/ml/g or≥3 positive cores or≥1 biopsy core with>50% involvement; Goto’s criteria, Gleason score≥7 or maximum
cancer core length ≥2 mm; GS, Gleason score; MRI, magnetic resonance imaging; MP-MRI, multi-parametric magnetic resonance imaging; NA, not available; NPV, negative predictive value; P, prospective; PPV,
positive predictive value; R, retrospective; Sen, sensitivity; Spe, specificity; TPMB, transperineal prostate mapping biopsy; UCL1, University College of London definition 1 (Gleason score ≥4+3 and/or maximum
cancer core length ≥6 mm and/or total cancer core length ≥6 mm); UCL2, University College of London definition 2 (Gleason score ≥3+4 and/or maximum cancer core length ≥4 mm and/or total cancer core
length ≥6 mm); US, ultrasound.
aThree independent multi-parametric magnetic resonance imaging readers.
bTwo different thresholds for clinically significant cancer suspicion at multi-parametric magnetic resonance imaging.
cOnly data on whole prostate level analysis are reported.
w
w
w
.fro
n
tiersin
.o
rg
N
ovem
ber
2014
|Volum
e
4
|A
rticle
294
|5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Giannarini et al. Multi-parametric MRI and significant prostate cancer
sufficiently accurate as a biparametric technique, the advantages
would be numerous. Compared to the other functional techniques,
in fact, DW-MRI requires no contrast medium administration,
no special software for image analysis, and no particular experi-
ence in image interpretation. Moreover, image analysis is faster
and less expensive, and quantitative data can be used to pre-
dict PCa grading. Therefore, this biparametric technique could
be applied to broader clinical settings, including larger patient
populations, such as those for screening and early detection
programs.
Active surveillance (AS) is an emerging treatment option for
most low- and some intermediate-risk PCa patients with the
aim of reducing overtreatment of indolent disease. Eligibility cri-
teria in all representative AS protocols are based on standard
clinico-pathological variables, which are inaccurate to predict
“clinically significant disease.” The risk of misclassification is,
thus, a major problem. With this regard, MP-MRI could be a
useful tool both to determine initial eligibility for AS and to
monitor disease progression. MP-MRI performed early after an
initial standard TRUS-guided PB suggesting histological suitabil-
ity for AS could exclude immediately those misclassified patients
(approximately 30%) with “clinically significant disease” (24).
However, it remains to be determined whether the adoption of
a MP-MRI-based pathway with targeted PB is superior to, e.g.,
a systematic saturation PB as a reclassification tool at entry in
AS protocols, the latter being clearly less expensive. Identifying
tumor progression during AS is also a major challenge, given
the inaccuracy of the standard clinical and histological para-
meters. MP-MRI could then significantly reduce the number of
unnecessary surveillance biopsies, thereby making AS less inva-
sive. Unfortunately, there is no currently accepted definition of
“radiological” progression. It is likely that this will be based
both on morphological parameters (e.g., lesion size/volume) and
functional parameters (e.g., changes in qualitative and quan-
titative parameters derived from functional sequences such as
DWI and DCE).
CONCLUSION
MP-MRI is an emerging imaging modality for diagnosis, stag-
ing, characterization, and treatment planning of PCa. There is
accumulating evidence suggesting a high accuracy of MP-MRI in
ruling out “clinically significant disease.” MP-MRI should, thus,
be further evaluated for application in different clinical scenarios
in which it is desirable to reduce the proportion of unnecessary
PBs and to limit the detection of indolent disease, such as oppor-
tunistic screening, persistent PCa suspicion in men with previous
negative PB, and eligibility for AS. Continued improvement in
standardization of technical parameters, functional sequences, and
image reporting systems is a pre-requisite for a rapid and successful
dissemination of this imaging modality.
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